| Q64065012 | "I am still negative": Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa |
| Q37500910 | "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya |
| Q64235019 | "We are not the same": African women's view of multipurpose prevention products in the TRIO clinical study |
| Q48218838 | A Randomized Crossover Study Evaluating the Use and Acceptability of the SILCS Diaphragm Compared to Vaginal Applicators for Vaginal Gel Delivery |
| Q59330342 | A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence? |
| Q38850472 | Acceptability and use of a dapivirine vaginal ring in a phase III trial |
| Q89689518 | Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077 |
| Q38678280 | Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States |
| Q62488014 | Accuracy of HIV Risk Perception in East Zimbabwe 2003-2013 |
| Q37159067 | Adherence and the Lie in a HIV Prevention Clinical Trial. |
| Q34180658 | An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings |
| Q35873971 | Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging. |
| Q28085433 | Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis |
| Q92062389 | Application of the HIV prevention cascade to identify, develop and evaluate interventions to improve use of prevention methods: examples from a study in east Zimbabwe |
| Q40051935 | Are you PEPped and PrEPped for travel? Risk mitigation of HIV infection for travelers. |
| Q38678847 | Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey |
| Q39848290 | Attrition and Opportunities Along the HIV Care Continuum: Findings From a Population-Based Sample, North West Province, South Africa |
| Q54233634 | Biomedical Approaches to HIV Prevention in Women. |
| Q48093922 | Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. |
| Q35187148 | Clinical Trial Design for HIV Prevention Research: Determining Standards of Prevention |
| Q40465731 | Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). |
| Q50028271 | Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05). |
| Q36421474 | Condoms, Lubricants and Rectal Cleansing: Practices Associated with Heterosexual Penile-Anal Intercourse Amongst Participants in an HIV Prevention Trial in South Africa, Uganda and Zimbabwe |
| Q50114646 | Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study |
| Q90588187 | Contraception as a Potential Gateway to Pre-Exposure Prophylaxis: US Women's Pre-Exposure Prophylaxis Modality Preferences Align with Their Birth Control Practices |
| Q53751650 | Designing and developing suppository formulations for anti-HIV drug delivery. |
| Q30674432 | Disclosure of pharmacokinetic drug results to understand nonadherence |
| Q27300707 | Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study |
| Q28550904 | Drivers of Vaginal Drug Delivery System Acceptability from Internet-Based Conjoint Analysis |
| Q59810828 | Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa |
| Q64137772 | Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques |
| Q34214499 | Elements of Condom-Use Decision Making among South African Men Who Have Sex with Men |
| Q45980808 | End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa. |
| Q64060141 | End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study |
| Q34180621 | Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction |
| Q37736062 | Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework |
| Q55343873 | Exploring HIV risks, testing and prevention among sub-Saharan African community members in Australia. |
| Q28546083 | Facilitators of adherence to the study pill in the FEM-PrEP clinical trial |
| Q27318158 | Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. |
| Q38616485 | Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial |
| Q92961793 | Factors associated with knowledge of pre-exposure prophylaxis in pregnant women in Cape Town, South Africa |
| Q40985895 | Gendered differences in the perceived risks and benefits of oral PrEP among HIV-serodiscordant couples in Kenya |
| Q90254973 | Generating CHARISMA: Development of an Intervention to Help Women Build Agency and Safety in Their Relationships While Using PrEP for HIV Prevention |
| Q37358616 | Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection. |
| Q46119171 | HIV and adolescents: focus on young key populations |
| Q33848307 | HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial |
| Q92063126 | HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery |
| Q64897103 | HIV-Related Communication and Safe Sex Practices among Heterosexual Black Men: A Qualitative Report. |
| Q36580115 | I Knew I Would Be Safer. Experiences of Kenyan HIV Serodiscordant Couples Soon After Pre-Exposure Prophylaxis (PrEP) Initiation |
| Q56909378 | Impact of partner-related social harms on women's adherence to the dapivirine vaginal ring during a phase III trial |
| Q46205436 | Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex. |
| Q35602506 | Implementation Research for the Prevention of Mother-to-Child HIV Transmission in Sub-Saharan Africa: Existing Evidence, Current Gaps, and New Opportunities |
| Q38849514 | Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial |
| Q33971596 | Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa |
| Q26786887 | Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies |
| Q41640436 | Innovative sensory methods to access acceptability of mixed polymer semisoft ovules for microbicide applications |
| Q54961974 | Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1 serodiscordant couples in East Africa: a qualitative evaluation study in Uganda. |
| Q37341579 | Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study |
| Q36451510 | Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana |
| Q58371158 | Love, Trust, and HIV Risk Among Female Sex Workers and Their Intimate Male Partners |
| Q35561488 | Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". |
| Q38794119 | Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty |
| Q50194198 | Motivated Reasoning and HIV Risk? Views on Relationships, Trust, and Risk from Young Women in Cape Town, South Africa, and Implications for Oral PrEP. |
| Q47107885 | Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography. |
| Q99638461 | Motivations for PrEP-Related Interpersonal Communication Among Women Who Inject Drugs: A Qualitative Egocentric Network Study |
| Q90709655 | Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis |
| Q47930607 | Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention |
| Q60920145 | Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa |
| Q36837446 | Negotiating the use of female-initiated HIV prevention methods in a context of gender-based violence: the narrative of rape. |
| Q51064420 | Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". |
| Q52323543 | Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling. |
| Q56911319 | Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships |
| Q38853819 | Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis |
| Q42668432 | Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design |
| Q35561492 | Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial |
| Q58091304 | Perceptions of the "Fabric" - An exploratory study of a novel multi-purpose technology among women in Sub Saharan Africa |
| Q57172735 | Perspectives of South African youth in the development of an implant for HIV prevention |
| Q64093995 | Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions |
| Q34606593 | Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis |
| Q34180615 | Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa |
| Q90693843 | PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples |
| Q43241737 | PrEP Implementation Science: State-of-the-Art and Research Agenda |
| Q42696079 | PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships |
| Q64113888 | PrEP and the syndemic of substance use, violence, and HIV among female and male sex workers: a qualitative study in Kisumu, Kenya |
| Q37352576 | PrEP implementation research in Africa: what is new? |
| Q94671913 | PrEP rollout in Africa: status and opportunity |
| Q37118864 | Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions |
| Q52612456 | Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
| Q26849762 | Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review |
| Q35875719 | Pre-exposure prophylaxis in Southern Africa: feasible or not? |
| Q34700364 | Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception |
| Q38260862 | Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs |
| Q92213693 | Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa |
| Q26796724 | Protocol for a systematic review: understanding the motivations and barriers to uptake and use of female-initiated, primary biomedical HIV prevention technologies in sub-Saharan Africa |
| Q57807578 | Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories |
| Q35061678 | Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally |
| Q38852654 | Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit? |
| Q35875710 | Rethinking HIV prevention to prepare for oral PrEP implementation for young African women |
| Q35415972 | Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women. |
| Q43201412 | Safer Conception Strategies for HIV-Serodiscordant Couples: How Safe Is Safe Enough? |
| Q39265007 | Sharing of Investigational Drug Among Participants in the Voice Trial |
| Q36952395 | Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study |
| Q35602771 | Sustained High HIV Incidence in Young Women in Southern Africa: Social, Behavioral, and Structural Factors and Emerging Intervention Approaches |
| Q36005787 | Synergies, tensions and challenges in HIV prevention, treatment and cure research: exploratory conversations with HIV experts in South Africa |
| Q35131207 | Tailored combination prevention packages and PrEP for young key populations |
| Q36443803 | Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women |
| Q30621914 | Tenofovir-based preexposure prophylaxis for HIV infection among African women |
| Q92324996 | The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth |
| Q90124011 | The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study |
| Q36160177 | The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers |
| Q40263565 | Time to Make the Jump: Translating HIV Pre-exposure Prophylaxis Research Into Real-World Public Health Impact |
| Q34086820 | Topical microbicides and HIV prevention in the female genital tract |
| Q37312664 | Treatment And Prevention for female Sex workers in South Africa: protocol for the TAPS Demonstration Project |
| Q92062957 | Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale-up: a synthesis of evidence from sub-Saharan Africa |
| Q89840867 | Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study |
| Q37685657 | Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. |
| Q37194802 | Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women |
| Q93031507 | Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: A feasibility study |
| Q37736077 | Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature |
| Q46553256 | Women and ARV-based prevention: opportunities and challenges |
| Q36728424 | Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts |
| Q64253938 | Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa |